title: A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation.
abstract: Hepatitis B virus envelope glycoproteins Large (L), Middle (M) and Small (S) are targets of the host cellular immune system. The extent to which the host recognizes viral antigens presented by infected cells is believed to play a decisive role in determining if an infection will be resolved or become chronic. As with other antigens, HBV envelope polypeptides must be degraded, presumably by cellular proteasomes, to be presented by the MHC I pathway. We have used M as a model to study this process and determine how ER quality control monitors these foreign polymeric proteins and disposes of them through the ER-associated degradation (ERAD) pathway. Using both wild type and mutant HBV M protein, we found that unlike most ERAD substrates, which require ubiquitination for retrotranslocation and degradation, the HBV M protein, which only contains two lysine residues, can undergo rapid and complete, ubiquitin independent, proteasome dependent degradation. The utilization of this pathway had a functional consequence, since proteins degraded through it, were poorly presented via MHC I. To test the hypothesis that the level of ubiquitination, independent of protein degradation, controls the level of antigen presentation, we inserted two additional lysines into both the wild type and mutant M protein. Amazingly, while the addition of the lysine residues dramatically increased the level of ubiquitination, it did not alter the rate of degradation. However and remarkably, the increased ubiquitination was associated with a dramatic increase in the level of antigen presentation. In conclusion, using the HBV surface protein as a model, we have identified a novel ubiquitin independent degradation pathway and determined that this pathway can have implications for antigen presentation and potentially viral pathogenesis.
authors.affiliation: Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, United States of America.
authors.forename: Yuanjie
authors.initials: Y
authors.lastname: Liu
authors.forename: James S
authors.initials: JS
authors.lastname: Testa
authors.forename: Ramila
authors.initials: R
authors.lastname: Philip
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Block
authors.forename: Anand S
authors.initials: AS
authors.lastname: Mehta
mesh_terms: D017951:Antigen Presentation; D003600:Cytosol / Q000378:metabolism; D057809:HEK293 Cells; D006515:Hepatitis B virus / Q000378:metabolism*; D006801:Humans; D008247:Lysosomes / Q000378:metabolism; D010455:Peptides / Q000737:chemistry; D011134:Polysaccharides / Q000737:chemistry; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry; D020033:Protein Isoforms; D011499:Protein Processing, Post-Translational; D059748:Proteolysis; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism; D025801:Ubiquitin / Q000737:chemistry*; D054875:Ubiquitination; D014759:Viral Envelope Proteins / Q000737:chemistry*
chemical_list: D010455:Peptides; D011134:Polysaccharides; D020033:Protein Isoforms; D025801:Ubiquitin; D014759:Viral Envelope Proteins; D046988:Proteasome Endopeptidase Complex